The Dales Report | Trade to Black

On our latest Trade To Black podcast, Host Shadd Dales & Anthony Varrell will break down the key takeaways from today’s ALJ hearing on the rescheduling of cannabis.

With the US Election, there has been a renewed interest in psychedelic stocks, driven by RFK Jr.’s recent comments on psychedelic research and his strong critique of the pharmaceutical industry, labeling America as one of the sickest countries in the world. This renewed focus has placed a spotlight on the psychedelic industry, which is conducting critical mental health trials to address conditions such as depression, anxiety, and PTSD.

The episode will cover 24 companies with over a $2 million market cap, including 18 micro-cap and 6 small-cap stocks. Of these, we’ll identify which companies are leading in 1-year returns and which are lagging.

Happy Friday, everyone!

On our latest Trade To Black podcast, Shadd and Anthony discuss why the U.S. Department of Health and Human Services (HHS) rejected a request from the DEA to provide witnesses for the upcoming ALJ hearing on December 2, 2024, in Arlington, Virginia, concerning the rescheduling of cannabis.

On our latest Trade To Black podcast, hosts Shadd Dales and Anthony Varrell are joined by Michael Bronstein from ATACH.

Cybin (NYSE:CYBN) CEO Doug Drysdale, discusses the company’s groundbreaking results announced on Monday, November 18th.

On our latest Trade To Black podcast, hosts Shadd Dales and Anthony Varrell break down some of the pressing headlines from this week.

We talk Canada featuring a panel of Canadian executives sharing their insights on the future of the Canadian cannabis landscape.

On our latest Trade To Black podcast, South Carolina Congresswoman Nancy Mace joins us to discuss cannabis reform and why she feels confident that progress can be made, based on recent appointee announcements by the Trump administration last week.

Cybin (NYSE:CYBN) CEO Doug Drysdale will join us to discuss their latest trials, where they reported a 71% remission rate in patients with major depressive disorder (MDD) for their leading compound, CYB003. We’ll ask what’s next regarding their Phase III trial and the performance of the psychedelic stock.